Compare ADMA Biologics Inc (ADMA) vs Icl Group Ltd (ICL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Icl Group Ltd — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Icl Group Ltd trades at $5.08 (market cap $6.49B). The key difference: Icl Group Ltd is far larger — about 3× ADMA Biologics Inc's market cap, and Icl Group Ltd pays a 3.85% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | ICL | |
|---|---|---|
Market Cap | $2.13B | $6.49B |
Sector | Health | Basic Materials |
52-Week High | $20.38 | $7.23 |
52-Week Low | $7.60 | $4.80 |
Enterprise Value | $2.20B | $9.06B |
Dividend Yield | — | 3.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
ICL trades at $4.95, down 1.59% on the day, with a bearish technical signal. The company reported Q1 2026 earnings of $0.11 per share, beating estimates, and announced a $0.05 dividend for H1 2026. Revenue for 2025 was $7.15B with a net income margin of 3.52%, while valuation metrics show a P/E of 24.05 and P/S of 0.88. Recent news highlights the completion of an $800 million senior notes offering to manage debt.
The outlook is mixed; strong cash flow and dividend payments provide stability, but declining profit margins and bearish analyst sentiment pose risks. Investment opportunity lies in operational improvements and potash market exposure, though investors face headwinds from raw material costs and foreign exchange volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
